McCubrey, James A.

Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy

Chang, F., Lee, J. T., Navolanic, P. M., Steelman, L. S., Shelton, J. G., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia

PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and Cancer

Cited by 1,176

Senescence-Associated Exosome Release from Human Prostate Cancer Cells

Lehmann, B. D., Paine, M. S., Brooks, A. M., McCubrey, J. A., Renegar, R. H., Wang, R., & Terrian, D. M. (2008) · Cancer Research

Extracellular vesicles in diseaseTelomeres, Telomerase, and Senescence

Cited by 464

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer

Duda, P., Akula, S. M., Abrams, S. L., Steelman, L. S., Martelli, A. M., Cocco, L., Ratti, S., Candido, S., Libra, M., Montalto, G., et al. (2020) · Cells

Wnt/β-catenin signaling in development and cancerPI3K/AKT/mTOR signaling in cancer

Cited by 284

PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches

Ligresti, G., Militello, L., Steelman, L. S., Cavallaro, A., Basile, F., Nicoletti, F., Stivala, F., McCubrey, J. A., & Libra, M. (2009) · Cell Cycle

PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and Cancer

Cited by 214

Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression

McCubrey, J. A., Yang, L. V., Abrams, S. L., Steelman, L. S., Follo, M. Y., Cocco, L., Ratti, S., Martelli, A. M., Augello, G., & Cervello, M. (2022) · Cells

Pancreatic and Hepatic Oncology ResearchMicroRNA in disease regulation

Cited by 49

PKR Regulates B56α-mediated BCL2 Phosphatase Activity in Acute Lymphoblastic Leukemia-derived REH Cells

Ruvolo, V. R., Kurinna, S. M., Karanjeet, K. B., Schuster, T. F., Martelli, A. M., McCubrey, J. A., & Ruvolo, P. P. (2008) · Journal of Biological Chemistry

Cell death mechanisms and regulationProtein Kinase Regulation and GTPase Signaling

Cited by 48

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes

Follo, M. Y., Pellagatti, A., Armstrong, R. N., Ratti, S., Mongiorgi, S., De Fanti, S., Bochicchio, M. T., Russo, D., Gobbi, M., Miglino, M., et al. (2019) · Leukemia

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 36

Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals

Abrams, S. L., Lertpiriyapong, K., Yang, L. V., Martelli, A. M., Cocco, L., Ratti, S., Falasca, M., Murata, R. M., Rosalen, P. L., Lombardi, P., et al. (2018) · Advances in Biological Regulation

Pancreatic and Hepatic Oncology ResearchCancer-related Molecular Pathways

Cited by 36

Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties

McCubrey, J. A., Meher, A. K., Akula, S. M., Abrams, S. L., Steelman, L. S., LaHair, M. M., Franklin, R. A., Martelli, A. M., Ratti, S., Cocco, L., et al. (2022) · Aging

Cancer-related Molecular PathwaysPancreatic and Hepatic Oncology Research

Cited by 12